Dade sells urinalysis tests to Quidel:
This article was originally published in Clinica
Executive Summary
US point-of-care diagnostics company Quidel has completed the acquisition of Dade Behring's Rapignost urine test strip business. "Urinalysis tests are important tools for the physician's overall assessment of patient health and will complement Quidel's existing point-of-care business," said the San Diego, California-based company's vice-chairman, president and CEO, Andre de Bruin. "The addition of this product line is expected to contribute to our near-term revenue and profit growth because it can be included within our existing sales and distribution structure." Financial details were not disclosed.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.